7 results
8-K
EX-99.2
LIANY
LianBio
10 Nov 22
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
Generation of Chinese Biotechs: Speed, Scale and Sustainable Growth 6 Commercial Model Provides Optionality Integrated commercial infrastructure built around … Development Status1 7
8 Three Key Pillars for Patient Reach and Sustainable Growth Mavacamten TP-03 Infigratinib BBP-398 Sisunatovir * All clinically
8-K
EX-99.2
LIANY
LianBio
11 Aug 22
LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:30pm
of Chinese Biotechs: Speed, Scale and Sustainable Growth 6 Commercial Model Provides Optionality Integrated commercial infrastructure built around core … States. Clinically ValidatedGlobal Development Status1 7
8 Three Key Pillars for Patient Reach and Sustainable Growth Mavacamten TP-03 Infigratinib BBP
8-K
EX-99.2
LIANY
LianBio
12 May 22
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
and commercial opportunity
…LianBio Positioned to Potentially Lead Next Generation of Chinese Biotechs: Speed, Scale and Sustainable Growth 6 Commercial … and Sustainable Growth Mavacamten TP-03 Infigratinib BBP-398 Sisunatovir * All clinically validated* CardiovascularOncology Inflammatory Diseases
10-K
2021 FY
LIANY
LianBio
31 Mar 22
Annual report
8:55am
more impartial and appropriate, improving the robust and sustainable operating mechanism for funds raised, establishing more effective and efficient
8-K
EX-99.1
LIANY
LianBio
2 Mar 22
Regulation FD Disclosure
4:42pm
…LianBio Positioned to Potentially Lead Next Generation of Chinese Biotechs: Speed, Scale and Sustainable Growth 6 Commercial Model Provides Optionality … for Patient Reach and Sustainable Growth Mavacamten TP-03 Infigratinib BBP-398 Omilancor NX-13 Sisunatovir * All clinically validated
DRS/A
b98qj2pa
9 Aug 21
Draft registration statement (amended)
12:00am
DRS
tjigej
28 Jun 21
Draft registration statement
12:00am
- Prev
- 1
- Next